The Technical AnalystExchange: EURONEXT Sector: Healthcare Industry: Medical Devices
Affluent Medical SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.78% €1.655
America/New_York / 17 mai 2024 @ 10:34
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 54.39 mill |
| EPS: | -0.540 |
| P/E: | -3.06 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 32.86 mill |
| Avg Daily Volume: | 0.0103 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.06 | sector: PE 17.08 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -3.06 | industry: PE 60.12 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 1.587 - 1.733 ( +/- 4.40%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | €1.655 (-1.78% ) |
| Volume | 0.0053 mill |
| Avg. Vol. | 0.0103 mill |
| % of Avg. Vol | 51.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AFME.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AFME.PA
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.